Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

This was the stock's third consecutive day of losses.

Becton Dickinson (BDX) explores divesting its $21B life sciences unit, engaging with rivals like Thermo Fisher (TMO) & ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 ...

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.

In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday. A number of other equities ...

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm ...

Shares of Becton, Dickinson and Company stock opened at $226.04 on Wednesday. The company’s 50 day moving average price is $231.38 and its two-hundred day moving average price is $231.62. The ...

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.